Novel influenza A

Novel influenza A is a viral disease entity used for influenza A virus infections of novel subtype or origin rather than routine seasonal circulation, and the provided metadata links it to ICD-10 J09 and ICD-11 1E30.0 [disease metadata]. The source literature describes novel influenza A viruses as zoonotic influenza A viruses of avian or swine origin that can cross species barriers and, under some circumstances, adapt for sustained transmission in humans ^[1][2]. In public-health terms, this label is most relevant when a newly emergent influenza A virus is being monitored for pandemic potential rather than when describing ordinary seasonal influenza ^[2].

The source evidence indicates an influenza syndrome characterized by abrupt onset of respiratory symptoms and myalgia, with or without fever, and recovery within about 1 week for most people ^[1]. It also notes that some cases can progress to severe or fatal complications, but it does not specify which complications are most important for this registry page ^[1]. No source-backed detail is available here on incubation period, specific organ involvement, or risk-stratified clinical course for novel influenza A beyond the general influenza description ^[1].

The available sources place influenza A as a major contributor to annual seasonal influenza epidemics with substantial worldwide disease burden, while also noting that seasonal circulation declined markedly in 2020–21 and increased again in 2021–22 ^[1]. For novel influenza A specifically, the surveillance concern is sporadic zoonotic infection from avian or swine viruses and the possibility that a new virus could acquire efficient human transmission and trigger a pandemic ^[1][2]. The reservoir described in the source material is broad and antigenically varied, with wild aquatic birds highlighted as a setting where infection is typically asymptomatic ^[2]. Source-backed detail on country-specific incidence, seasonality for this registry entity, or outbreak counts is not yet available ^[1][2].

The source material indicates that novel influenza A transmission is primarily a concern when a zoonotic influenza A virus crosses from animal reservoirs into humans, especially from avian or swine origins ^[1][2]. Pandemic emergence is framed as occurring when such a virus not only infects a new host species but also transmits efficiently between people ^[2]. No source-backed detail is available here on specific exposure settings, environmental persistence, or the relative importance of droplet, aerosol, or contact pathways for this registry entity ^[2].

The source material identifies exposure to avian or swine influenza A viruses as the relevant ecological risk context, and it specifically notes wild aquatic birds as a reservoir in which infection is typically asymptomatic ^[2]. Beyond that, the provided snippets do not define clinical high-risk groups, occupational groups, or age-specific vulnerability for this registry entity ^[1][2].

Prevention in the broader influenza literature is described as being primarily through annual influenza vaccination, with efforts ongoing to improve vaccine effectiveness ^[1]. The source also notes that antiviral post-exposure prophylaxis with neuraminidase inhibitors can reduce the incidence of influenza and symptomatic influenza, although the efficacy of other antiviral classes remains unclear ^[3]. For novel influenza A, the available evidence further supports the importance of infection prevention and non-pharmaceutical interventions, but source-backed operational details are not yet available in the provided snippets ^[1][2].

In surveillance practice, this entity should be read as a sentinel signal for emergence of a novel influenza A virus rather than as ordinary seasonal influenza alone, because the public-health significance lies in cross-species spillover and adaptation to human transmission ^[2]. The source literature highlights the need to track both viral and host factors, since pandemic risk depends on the virus acquiring enough adaptive change to sustain spread between people ^[2]. Source-backed detail on alert thresholds, reporting intervals, or formal case ascertainment criteria is not yet available in the provided material ^[2].

1. 1 Uyeki TM et al. Influenza. Lancet. 2022 Aug 27. PMID: 36030813. doi: 10.1016/S0140-6736(22)00982-5. PubMed: https://pubmed.ncbi.nlm.nih.gov/36030813/
2. 2 AbuBakar U et al. Avian Influenza Virus Tropism in Humans. Viruses. 2023 Mar 24. PMID: 37112812. doi: 10.3390/v15040833. PubMed: https://pubmed.ncbi.nlm.nih.gov/37112812/
3. 3 Zhao Y et al. Antivirals for post-exposure prophylaxis of influenza: a systematic review and network meta-analysis. Lancet. 2024 Aug 24. PMID: 39181596. doi: 10.1016/S0140-6736(24)01357-6. PubMed: https://pubmed.ncbi.nlm.nih.gov/39181596/
4. 4 Novel Influenza A(H1N1). Pediatric Emergency Care. 2009. doi: 10.1097/pec.0b013e3181c3c8f8. DOI: https://doi.org/10.1097/pec.0b013e3181c3c8f8
5. 5 Novel Influenza Viruses. Clinical Microbiology Procedures Handbook. 2016. doi: 10.1128/9781555818814.ch16.11. DOI: https://doi.org/10.1128/9781555818814.ch16.11
6. 6 Wikidata contributors. Novel Influenza A (H1N1) Surveillance Registry [Internet]. Wikidata. cited 20 May 2026. Available from: https://www.wikidata.org/wiki/Q64658484

ICD-10

J09

ICD-11

1E30.0

Total cases

37K

Total deaths

1

Peak month

2009-09

Coverage

8 reporting countries · 2000-01-01 → 2026-06-20